Antiplatelet use and CADASIL: a retrospective observational analysis

Muppa, Jayachandra; Yaghi, Shadi; Goldstein, Eric

doi:10.1007/s10072-023-06773-1

Cited by 4 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CADASIL is a prevalent hereditary stroke disease caused by mutations in the NOTCH3 gene (17), typically expressed in VSMCs and The emergency computer tomography perfusion (A) of the proband reveals that the cerebral blood flow and volume in the low-density area of the left temporo-parieto-occipital insular lobe were lower than those on the contralateral side. Additionally, the mean transit time, time to peak, and T max were longer than those on the contralateral side; the volume of the core infarct area was 48.6 mL, and the mismatch volume was 41.8 mL.…”

Section: Discussionmentioning

confidence: 99%

“…CADASIL is a prevalent hereditary stroke disease caused by mutations in the NOTCH3 gene ( 17 ), typically expressed in VSMCs and pericytes ( 18 ). Degeneration and apoptosis of VSMCs and pericytes occur, resulting in impaired cerebrovascular reactivity and disruption of the blood–brain barrier ( 19 , 20 ).…”

Section: Discussionmentioning

confidence: 99%

“…Though, current evidence does not substantiate a clear link between the occurrence of ICH and the usage of antiplatelet drugs. According to reports, Muppa et al conducted a clinical study on whether the use of antiplatelet drugs affected the incidence of AIS or ICH in patients with CADASIL ( 17 ). They included 455 patients with CADASIL and obtained negative results, indicating no significant difference in AIS or ICH events after receiving antiplatelet drug treatment.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment options for patients with CADASIL and large-scale cerebral infarction: mechanical thrombectomy and antiplatelet therapy—A case report

Xiao,

Ke,

Cai

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

BackgroundCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant inherited arterial disease, with lacunar infarction resulting from intracranial small vessel lesions being the most prevalent clinical manifestation of CADASIL. However, large-scale cerebral infarction caused by intracranial non-small vessels occlusion is relatively uncommon, and reports of vascular intervention and long-term antiplatelet drug treatment for patients with CADASIL and large-scale cerebral infarction are rarer.MethodsWe reported a 52 year-old male who experienced a significant cerebral infarction due to an occlusion in the second segment of the left middle cerebral artery, 4 months subsequent to being diagnosed with CADASIL. Following the benefit and risk assessment, the patient underwent intracranial vascular thrombectomy and balloon dilation angioplasty. Subsequently, he was administered dual antiplatelet therapy for 3 months, followed by mono antiplatelet therapy.ResultsAfter undergoing intracranial vascular intervention and receiving antiplatelet therapy, significant improvement in the symptoms were observed. The National Institutes of Health Stroke Scale score decreased from 6 to 2 points, and no bleeding lesions were detected on the head computed tomography during regular follow-up visits after discharge.ConclusionOur case highlights the possibility that patients with CADASIL may also encounter extensive cerebral infarction resulting from stenosis or occlusion of intracranial non-small vessels. Considering the specific circumstances of the patient, intravascular intervention and antiplatelet therapy can be regarded as viable treatment options for individuals with CADASIL.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment options for patients with CADASIL and large-scale cerebral infarction: mechanical thrombectomy and antiplatelet therapy—A case report

Xiao,

Ke,

Cai

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Though, current evidence does not substantiate a clear link between the occurrence of ICH and the usage of antiplatelet drugs. According to reports, Muppa et al conducted a clinical study on whether the use of antiplatelet drugs affected the incidence of AIS or ICH in patients with CADASIL (17). They included 455 patients with CADASIL and obtained negative results, indicating no significant difference in AIS or ICH events after receiving antiplatelet drug treatment.…”

Section: Discussionmentioning

confidence: 99%

Data_Sheet_1.docx

View full text Add to dashboard Cite

2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association

Bushnell,

Kernan,

Sharrief

et al. 2024

Stroke

View full text Add to dashboard Cite

AIM: The “2024 Guideline for the Primary Prevention of Stroke” replaces the 2014 “Guidelines for the Primary Prevention of Stroke.” This updated guideline is intended to be a resource for clinicians to use to guide various prevention strategies for individuals with no history of stroke. METHODS: A comprehensive search for literature published since the 2014 guideline; derived from research involving human participants published in English; and indexed in MEDLINE, PubMed, Cochrane Library, and other selected and relevant databases was conducted between May and November 2023. Other documents on related subject matter previously published by the American Heart Association were also reviewed. STRUCTURE: Ischemic and hemorrhagic strokes lead to significant disability but, most important, are preventable. The 2024 primary prevention of stroke guideline provides recommendations based on current evidence for strategies to prevent stroke throughout the life span. These recommendations align with the American Heart Association’s Life’s Essential 8 for optimizing cardiovascular and brain health, in addition to preventing incident stroke. We also have added sex-specific recommendations for screening and prevention of stroke, which are new compared with the 2014 guideline. Many recommendations for similar risk factor prevention were updated, new topics were reviewed, and recommendations were created when supported by sufficient-quality published data.

show abstract

Antiplatelet use and CADASIL: a retrospective observational analysis

Cited by 4 publications

References 17 publications

Treatment options for patients with CADASIL and large-scale cerebral infarction: mechanical thrombectomy and antiplatelet therapy—A case report

Treatment options for patients with CADASIL and large-scale cerebral infarction: mechanical thrombectomy and antiplatelet therapy—A case report

Data_Sheet_1.docx

2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association

Contact Info

Product

Resources

About